Is Stomach Cancer the Same as Colon Cancer?

Stomach cancer and colon cancer are two distinct diseases that arise in different organs, follow different genetic pathways, respond to different risk factors, and carry different prognoses. Both belong to the broader family of gastrointestinal cancers, and both can involve glandular tissue, which is part of why people sometimes conflate them. But the distinctions between them matter enormously for prevention, screening, and treatment. The two cancers are even trending in opposite directions globally, with stomach cancer rates falling and colorectal cancer rates climbing in wealthier nations.

Where They Start and Why That Matters

The stomach and the colon are separated by roughly twenty feet of small intestine, and the lining of each organ is specialized for a different job. The stomach’s inner lining produces acid and enzymes to break down food. The colon’s lining absorbs water and electrolytes from the remnants that the small intestine has already processed. When cancer develops in either organ, it typically arises from the glandular cells of that lining, which is why both are often classified as adenocarcinomas. But similarities in cell type do not mean the cancers behave the same way. Research comparing specific subtypes across both organs has found that certain tumor patterns strongly prefer one location over the other. Mucinous adenocarcinomas, for example, tend to localize in the colorectal region, while signet-ring cell carcinomas are more common in the stomach.¹ These subtypes differ not just in where they grow but in how aggressive they are and how they respond to treatment.

Different Risk Factors Drive Each Cancer

If you wanted to reduce your risk of stomach cancer versus colon cancer, you would focus on largely different things. For stomach cancer, the single most important risk factor is infection with the bacterium Helicobacter pylori, which colonizes the stomach lining and drives chronic inflammation that can eventually lead to malignant changes.² Diet also plays a role, particularly high salt intake and consumption of preserved or pickled foods. A systematic review cataloging stomach cancer risk factors identified over fifty, grouped into categories including diet, lifestyle, genetic predisposition, infections, occupational exposures, and family history.³

Colon cancer risk, by contrast, is most strongly linked to red and processed meat consumption, obesity, physical inactivity, alcohol use, and smoking. H. pylori is not a meaningful player here. A comprehensive meta-analysis of prospective studies found that red meat consumption raised colon cancer risk by about 22%, and processed meat by about 13%.⁴ Even within the red meat category, the type matters: research has found that different meat subtypes carry different levels of risk for the colon versus the rectum specifically.⁵ The practical takeaway is that preventing stomach cancer and preventing colon cancer call for different strategies. Eradicating H. pylori in high-risk populations addresses stomach cancer but does nothing for the colon. Cutting back on processed meat and staying active addresses colon cancer risk but barely moves the needle for the stomach.

Genetic Pathways That Set Them Apart

At the molecular level, stomach and colon cancers accumulate mutations through overlapping but distinct pathways. Both can involve mutations in well-known cancer genes like TP53, KRAS, and APC, but the frequency and pattern of those mutations differ. A study comparing tumors from both organs found a total mutation frequency of about 47% in colorectal cancer samples but only about 13% in stomach cancer samples for those three genes. APC mutations, which are a hallmark of the classic colon cancer pathway, were the most common overall, followed by KRAS and TP53. The researchers concluded that these results point to different genetic pathways driving the two cancers.⁶

There is some overlap. Research on the p53 gene has shown that the pattern of p53 mutations in early-stage gastric cancer resembles the pattern seen in colorectal cancer, with a high rate of a specific type of DNA change at particular hotspots.⁷ So the two cancers are not genetically unrelated; they share some of the same molecular machinery going wrong. But they use that machinery differently. Another study looking at PIK3CA mutations found them in roughly 14% of colorectal cancers and 11% of gastric cancers, but with an important distinction: in colon cancer, PIK3CA mutations tended to occur alongside other activating mutations like KRAS or BRAF, while in gastric cancer they tended to occur alone.⁸ These differences are not just academic curiosities; they affect which targeted therapies might work for each cancer.

Global Trends Are Moving in Opposite Directions

One of the starkest differences between these two cancers is their population-level trajectory. Stomach cancer has been declining worldwide for decades. The age-standardized rates for prevalence, death, and disability from stomach cancer all trended downward between 1990 and 2021, with the disability rate dropping by more than half over that period.⁹ Much of this decline is attributed to better sanitation, reduced H. pylori prevalence, refrigeration replacing salt preservation of food, and declining smoking rates in some regions.

Colorectal cancer, meanwhile, is moving the other direction in wealthier countries and is forecast to keep rising over the coming decade.¹⁰ When researchers specifically examined early-onset cancers in people under fifty, colorectal cancer was the only gastrointestinal cancer with a rising incidence rate, while stomach cancer showed the steepest decline.¹¹ The factors behind the rise in colorectal cancer among younger adults are not fully understood, but likely involve dietary shifts toward highly processed foods, increasing obesity rates, and sedentary lifestyles in high-income countries.

Geography plays a big role in both cancers. Stomach cancer burden among younger adults is highest in East Asia, particularly Mongolia and parts of China, while colorectal cancer rates in the same age group are highest in places like Taiwan and other high-income Asian and Western nations.¹² Stomach cancer also affects men at a much higher rate than women, with the male prevalence rate roughly 2.7 times the female rate globally.⁹ Colorectal cancer also leans male but the gap is narrower.

Screening Looks Completely Different

In most Western countries, you have probably heard about colonoscopy or stool tests for colorectal cancer screening. That framework is well established. Guidelines recommend stool-based tests like the fecal immunochemical test (FIT) for adults starting around age 45 to 50, with colonoscopy used either as a primary screening tool or as a follow-up when stool tests come back positive.¹³ These programs are credited with catching precancerous polyps before they turn malignant, which is one reason colorectal cancer mortality has improved in countries with strong screening uptake.

Stomach cancer screening, by contrast, is not routine in most of the Western world. It is practiced mainly in countries where stomach cancer rates are high enough to justify it, particularly Japan and South Korea. In those countries, population-based programs have been running since the 1960s, using methods like X-ray photofluorography or blood tests measuring pepsinogen levels to identify people who need an upper endoscopy.¹⁴ European guidelines suggest that endoscopic stomach cancer screening could be considered for people over 40 in high-risk populations, but acknowledge that in regions with lower incidence, it is harder to justify the cost and resources.¹³

Interestingly, there is active research into combining stomach and colorectal cancer screening in certain European countries with intermediate stomach cancer rates. An analysis in Portugal found that pairing upper endoscopy with an already-scheduled screening colonoscopy could be cost-effective in countries where the stomach cancer rate exceeds a certain threshold.¹⁵ This highlights how differently the two cancers are managed at the public health level, and how your geographic location determines which screenings are even available to you.

How They Spread and Where They Go

When stomach cancer metastasizes, it favors certain destinations. A large study of metastatic gastric cancer patients found that the liver was the most common site of spread, involved in about 48% of cases, followed by the peritoneum (the lining of the abdominal cavity) in 32%, the lungs in 15%, and bone in 12%. The pattern was not uniform across tumor types: signet-ring cell adenocarcinomas, a particularly aggressive subtype, spread more frequently to the peritoneum, bone, and ovaries, while the more common generic adenocarcinomas favored the liver and lungs.¹⁶

Colorectal cancer follows a somewhat different metastatic map. The liver is again the most common destination, but that is largely because blood from the colon drains through the portal vein directly to the liver. Lung metastases are more common in rectal cancer than colon cancer because of different venous drainage. Peritoneal spread occurs in colorectal cancer too, but it tends to carry a different prognostic weight compared to stomach cancer. Research on microscopic peritoneal spread found that positive peritoneal cytology was a significant predictor of poor survival in gastric cancer patients after surgery but was not associated with worse outcomes in colon cancer patients who underwent the same type of analysis.¹⁷ This difference in how peritoneal spread affects prognosis reflects the broader trend that stomach cancer tends to behave more aggressively at similar stages.

Survival Rates Tell a Stark Story

Head-to-head comparisons consistently show that colorectal cancer patients survive longer than gastric cancer patients. One study that directly compared the two found one-year survival rates of about 91% for colorectal cancer versus 71% for stomach cancer, with the gap widening over time. By five years, roughly 61% of colorectal cancer patients were still alive compared to about 25% of stomach cancer patients. By seven years, it was 55% versus 20%.¹⁸ The survival advantage held across all levels of tumor differentiation and even in cases with distant metastasis. Part of this difference comes from the fact that stomach cancer is more often diagnosed at advanced stages, particularly in countries without routine screening. But even when stage is accounted for, stomach cancer tends to carry a worse prognosis.

When One Hereditary Syndrome Raises Risk for Both

Despite all their differences, stomach and colon cancer can occasionally share the same underlying genetic cause. Lynch syndrome is an inherited condition that dramatically raises the risk for multiple cancers. Colorectal and endometrial cancers are the most commonly associated, but people with Lynch syndrome also face elevated risk for stomach cancer, along with cancers of the small bowel, ovary, urinary tract, and brain.¹⁹ The syndrome involves defects in DNA mismatch repair genes, leading to a characteristic pattern called microsatellite instability (MSI). Tumors with high MSI, whether in the stomach or the colon, tend to respond better to immunotherapy. Research on checkpoint inhibitors like pembrolizumab has shown dramatically better outcomes in MSI-high colorectal tumors compared to MSI-low ones.²⁰ This is one of the rare instances where the molecular profile of a tumor matters more than its organ of origin for choosing treatment.

The existence of Lynch syndrome is sometimes what confuses people into thinking stomach and colon cancer are more closely related than they actually are. If a relative was diagnosed with both, or if family members had cancers in different gastrointestinal organs, Lynch syndrome may be the thread connecting them. But Lynch syndrome is relatively uncommon in the broader cancer population, and the vast majority of stomach and colon cancers arise independently through their own distinct pathways.

Treatment Approaches and Emerging Therapies

Surgery is the cornerstone of curative treatment for both cancers, but the operations involved are quite different. Removing part or all of the stomach (gastrectomy) carries different nutritional consequences than removing a section of the colon (colectomy). After gastrectomy, patients often struggle with eating adequate calories, absorbing certain nutrients like vitamin B12 and iron, and managing a condition called dumping syndrome where food moves too quickly into the small intestine. After colectomy, the main concerns tend to be changes in bowel habits and, depending on how much colon is removed, issues with hydration and electrolyte balance.

Surgery for recurrent or remnant stomach cancer can be particularly challenging. In cases where a patient had a previous stomach operation, adhesions and direct tumor invasion make the reoperation more difficult. These patients are often older and may already be malnourished, which complicates recovery. Despite the difficulty, curative surgery with lymph node removal remains the best option for improving survival in eligible patients.²¹

Beyond surgery, chemotherapy regimens differ between the two cancers. Colorectal cancer treatment commonly involves fluoropyrimidine-based regimens combined with oxaliplatin or irinotecan, and targeted therapies against VEGF or EGFR depending on molecular markers. Gastric cancer chemotherapy uses some of the same backbone drugs but often adds different agents, and HER2-targeted therapy plays a role in the subset of stomach cancers that overexpress that protein. The immunotherapy landscape, as noted in the context of MSI-high tumors, is an area where the two cancers converge somewhat, but access to these treatments still depends heavily on the tumor’s molecular profile rather than simply where it sits in the body.

Why People Confuse Them

Several things contribute to the mix-up. Both cancers can cause overlapping symptoms in their early stages, including vague abdominal discomfort, changes in appetite, unexplained weight loss, and blood in the stool (though this is more characteristic of colorectal cancer). Both are sometimes lumped under the umbrella of “GI cancers” in public health campaigns and news coverage, which can blur the distinctions. And both are adenocarcinomas in the majority of cases, which sounds like the same disease with a different address.

But thinking of them as the same disease would lead you astray in almost every practical way. You would look for the wrong risk factors, screen at the wrong time with the wrong test, expect the wrong prognosis, and potentially miss the right treatment approach. The two cancers share an organ system, but the story of how each one develops, whom it tends to affect, and how medicine fights it is fundamentally different.